Drugs / BKR-017
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03999853 | Jul 2022 → Apr 2025 | type 1 diabetes mellitus | Mayo Clinic | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-04-30 | BioKier Inc. | Results Results of 4-week BKR-017 study in type 2 diabetes subjects and ongoing activity biokier.com ↗
BKR-017 (sustained-release formulation) decreased circulating cholesterol. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-01-26 | BioKier Inc. | BioKier completed a 12-week clinical study of BKR-017 in type 2 diabetes patients biokier.com ↗ |
| 2022-04-30 | BioKier Inc. | Results of 4-week BKR-017 study in type 2 diabetes subjects and ongoing activity biokier.com ↗ |
| 2021-01-26 | BioKier Inc. | Completion of 4-week BKR-017 study in type 2 diabetes subjects and upcoming plans biokier.com ↗ |
| 2019-10-01 | BioKier Inc. | JDRF Awarded Grant to Conduct Study of BioKier Product, Butyrate Tablet, BKR-017, in Type 1 Diabetes Patients biokier.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BKR-017 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03999853 ↗ |